Objective: As antiretroviral therapy (ART) expands for HIV-infected children, it is important to determine its impact on growth. We quantified growth and its determinants following ART in resource-limited (RLS) and developed settings.
Introduction
Antiretroviral therapy (ART) has substantially decreased morbidity and mortality in HIV-infected children [1] [2] [3] [4] [5] . ART also results in marked improvements in weight and height in children. Of the 3.3 million children living with HIV, more than 90% reside in resource-limited settings (RLS) [6] . In these settings, malnutrition is prevalent and children may be delayed in receiving ART because of late diagnosis [5, 7] . Both of these issues contribute to suboptimal growth reconstitution. Given prevalent nutritional needs, pediatric HIV treatment programmes have varied approaches to nutritional supplementation during ART; with some empirically providing supplementation at initiation of ART [8] [9] [10] . It remains unclear whether ART alone or combined with nutritional supplements at initiation is better for long-term growth. It is well established, however, that suboptimal growth is associated with increased risk of mortality, repeat infections, and poor cognitive development [11] .
Marked growth reconstitution occurs following ART. Previous reviews of pediatric ART outcomes have focused primarily on immunologic and virologic response, and have been limited to sub-Saharan Africa [3, 12] or RLS [13] . In a review by Peacock-Villada et al. [14] , we noted marked differences in baseline CD4% and viral load, and post-ART mortality in HIV-infected children in resource-limited vs. developed countries. We performed a systematic review and meta-analysis to aggregate and compare growth outcomes following ART initiation among HIV-infected children in RLS and developed settings and to assess determinants of growth in these settings, including the role of nutritional supplementation in RLS.
Methods

Data search
A systematic literature search was conducted for all peerreviewed literature, published in English, reporting growth outcomes [(weight, length, height, weight-forage (WAZ), height-for-age (HAZ), length-for-age, and weight-for-height (WHZ) z scores] in HIV-1 infected children following ART initiation. We searched PubMed, Cochrane, Embase, and Global Health Host through August 2014, using combinations of the following search terms: growth, length, height, weight, Z-score, outcomes, children, pediatric, paediatric, antiretroviral therapy, ART, HAART, HIV. Bibliographies of relevant articles were also examined.
Study selection and inclusion/exclusion criteria
The following inclusion criteria were used to select publications: patients younger than18 years; patients initiating ART (!3 drugs); at least 20 patients; growth measures at ART initiation; and growth measures following 6, 12, or 24 months of ART. Outcome measures included the following growth parameters: WAZ, WHZ, and HAZ.
Studies reporting only clinical outcomes (CD4 þ cell count and HIV-1 RNA), limited to growth measures either prior to or following ART only, or lacking stated outcomes of interest were excluded. Articles were also excluded if the outcome of interest was analyzed in terms of weight (kg or pounds) and height (cm or in) without z score standardization.
Data extraction
Standardized data collection was used to extract all data, including pre-ART and post-ART z scores, nutritional supplementation, study objective, site, sample size, ART regimen, time on ART, and disease severity at initiation. Articles were classified as having been conducted in a 'RLS' or 'developed setting' based on the United Nations Statistics Division [15] , and further subcategorized by geographic location. Studies reporting results from the same cohort or treatment programme were compared, and only the most recent publication with relevant growth outcomes was included.
Statistical analysis
Primary outcomes of interest were change in z scores (WAZ, WHZ, and HAZ) at 6, 12, or 24 months post-ART. Data on mean or median change in growth post-ART were either collected directly or calculated from reported results. Change in z score [or standard deviation (SD)] was calculated using the following methods: difference between the baseline and 6, 12, or 24 month value; overall rate of change during 6-month, 12-month, or 24-month interval, as reported, or monthly rate of change in z score as reported from longitudinal analyses, specifically mixed-effects models for longitudinal data. The monthly rate of change estimations differ based on follow-up time as growth reconstitution generally peaks early followed by smaller incremental changes with longer duration on ART. Therefore, studies presenting changes in growth for 6 months may have a greater monthly change than those with 12 months follow-up (averaged over time). For studies reporting follow-up time in weeks, we included 24, 48, and 96 weeks as 6-month, 12-month, and 24-month growth outcomes.
Weighted baseline characteristics were compared between RLS and developed settings using a two-sample t-test assuming unequal variances, as appropriate. All means were weighted based on the reported sample size within the individual studies. When growth parameters were reported for only a subset of children with follow-up data, the weight for that parameter was adjusted based on reported size of the subset. Standardized mean differences were calculated for individual studies and overall weighted mean differences were calculated by setting (RLS vs. developed settings) and displayed graphically in a forest plot. Forest plots display both the weighted mean difference and confidence interval (CI) for each study, as shown by a black box and corresponding horizontal line, and the pooled weighted mean difference across all studies, depicted with a diamond. Using methods described in Hozo et al. [16] , the median, range, and sample size were used to estimate mean and variance where this information was not reported or available. We observed similar meta-analysis results when including means alone vs. combined means and medians; thus, results presented include both means and estimations of the mean using medians. Heterogeneity between studies was tested using x 2 tests and the summary I-squared statistic [17] . Random-effects meta-analysis regression models were conducted to account for heterogeneity between studies and to assess the effect of setting and cohort age on growth rate post-ART. Cohort age was defined as the mean or median for each study and categorized as less than 4 years, 4-6 years, and more than 6 years at ART. All analyses were conducted using STATA 13.0 (StataCorp LP, College Station, Texas, USA).
Results
Study selection and characteristics
Our search strategy identified 1836 potentially relevant articles. After review of abstracts, 223 articles were selected for full-article review. Of these articles, 167 were excluded based on reasons outlined in Fig. 1 . The remaining 67 articles fulfilled the inclusion criteria and were included for at least one of the primary growth analyses (RLS ¼ 54, total N ¼ 25 927; and developed settings ¼ 13, total N ¼ 1810). Table 1 describes characteristics of the included cohorts.
Baseline mean age and growth
The mean baseline age at ART initiation was 5.8 years (range, 0.1-16 years) in RLS and 6.6 years (range, 0-18 years) in developed settings (P ¼ 0.90) (Supplemental Table  1 , http://links.lww.com/QAD/A735). Baseline growth parameters were well below average (z score ¼ 0) in RLS children initiating ART. Mean baseline WAZ was À2.1 in RLS compared with À0.5 in developed settings (P < 0.01). Mean WHZ was lower in RLS vs. developed settings (À1.5 and 0.3, respectively, P ¼ 0.05). Mean HAZ was À2.2 in RLS vs. À0.9 in developed settings (P < 0.01).
Change in weight-for-age at 6, 12, and 24 months post-antiretroviral therapy Twenty-seven studies (RLS ¼ 33, N ¼ 16 841; and developed settings ¼ 6, N ¼ 713) reported WAZ at 6 months post-ART (Table 2) . Gains in WAZ ranged from 0.01 to 2.19 in RLS and À0.10 to 0.51 in developed settings. Twenty-nine studies (RLS ¼ 23, N ¼ 14 032; and developed settings ¼ 6, N ¼ 713) with data on mean or median WAZ were included in the estimate of the pooled mean difference ( Fig. 2a ). At 6 months post-ART, children in RLS gained 0.65 (95% CI 0.35-0.95) in WAZ compared with a gain of 0.19 (95% CI 0.08-0.29) in children in developed settings (P ¼ 0.095). After adjusting for cohort age, the 6 monthly rate of increase in WAZ did not differ between RLS and developed settings (0.32 SD; 95% CI À0.09 to 0.73; P ¼ 0.12).
At 12 months post-ART, 45 studies (RLS ¼ 36, N ¼ 17 087; and developed settings ¼ 9, N ¼ 1340) reported mean or median WAZ. Gains ranged from 0 to 3.20 in RLS and À0.20 to 0.53 in developed settings. Of the 36 studies (RLS ¼ 27, N ¼ 13 822; and developed settings ¼ 9, N ¼ 1340) included in the pooled estimate ( Fig. 2a ), children in RLS gained an average WAZ of 0.84 (95% CI 0.54-1.14) compared with 0.17 (95% CI 0.05-0.30) among children in developed settings (P ¼ 0.02). Twelve-month gains in WAZ remained greater in RLS than developed settings (0.56 SD; 95% CI 0.08-1.04; P ¼ 0.03) after adjusting for cohort age. for cohort age, the 2-year rate of increase in WAZ remained higher in RLS (0.60 SD, 95% CI 0.03-1.17; P ¼ 0.04). Figure 3 illustrates WAZ over time in 38 studies in RLS and 12 studies in developed settings.
Change in height-for-age at 6, 12, and 24 months post-antiretroviral therapy Six-month post-ART growth was reported in 31 studies (RLS ¼ 24, N ¼ 13 693; and developed settings ¼ 7, N ¼ 681) ( Table 2) . Change in 6-month HAZ ranged from À0.36 to 0.40 in RLS and from 0 to 0.83 in developed settings. Of the 26 studies (RLS ¼ 19, N ¼ 11 585; and developed settings ¼ 7, N ¼ 681) included in the pooled analysis ( Fig. 2b) , children in RLS and developed settings experienced similar 6-month gains in height (0.08, 95% CI 0.02-0.13; and 0.10, 95% CI À0.01 to 0.20, respectively, P ¼ 0.62). After adjusting for cohort age, there was no difference in 6-month HAZ gains by setting.
Thirty-eight studies (RLS ¼ 29, N ¼ 13 603; and developed settings ¼ 9, N ¼ 1295) reported HAZ at 12 months post-ART (Table 2) . Change in HAZ ranged from À0.30 to 1.65 in RLS and À0.01 to 0.70 in developed settings. Twenty-eight studies were included in pooled analysis (RLS ¼ 19, N ¼ 10 930; and developed settings ¼ 9, N ¼ 1295) (Fig. 2b) . Although not significantly different, children in RLS experienced a mean 12-month gain in HAZ of 0.23 (95% CI 0.14-0.33) compared with a gain of 0.12 (95% CI 0.03-0.21) in children in developed settings (P ¼ 0.73). This remained after adjusting for age.
Twenty-nine studies (RLS ¼ 21, N ¼ 8068; and developed settings ¼ 8, N ¼ 788) reported HAZ at 24 months post-ART ( Table 2 ). Pooled summary statistics were not performed because of the small number of studies reporting mean WHZ post-ART.
Potential cofactors for growth reconstitution
Age at ART initiation Eleven studies reported data regarding associations between age at initiation and post-ART growth [1, 22, 25, 26, 33, 37, 39, 42, 44, 56, 57, 73] . Nine of these (RLS ¼ 7 and developed settings ¼ 2) reported an association between younger age at ART initiation and greater improvements in WAZ [1, 22, 33, 37, 39, 42, 44, 56, 73] and HAZ [26, 33, 37, 39, 42, 56, 73] . The remaining two studies (Thailand [57] and Malawi [25] ) found no difference in growth and age at ART initiation. Adjusting for setting, older median cohort age was significantly associated with lower rate of change in weight (À0.07 SD per 1 year increase in age; 95% CI À0.12, À0.01; P ¼ 0.02) 12 months post-ART. Further, cohorts with median age less than 4 years at ART had greater rate of change in yearly WAZ as compared with cohorts aged more than 6 years at ART (0.52 SD; 95% CI 0.05-0.99; P ¼ 0.03). Similarly, younger cohorts (<4 years) had higher 6-month HAZ increase compared with older cohorts (>6 years) (0.15 SD, 95% CI 0.01-0.30; P ¼ 0.04), after adjusting for setting. The relationship between younger cohort age and greater improvements in HAZ did not persist beyond 6 months post-ART.
Nutrition supplementation and ART Information on nutrition supplementation was reported in fourteen studies, all in RLS. Types of supplementation included rice/corn and vegetable oil (Haiti [64] ), highenergy protein (Zambia [44] ), Plumpy'Nut (Nutriset, Normandy, France) (Malawi [25] ), other ready-to-use therapeutic food (Malawi [24] ), nutritional porridge (Kenya [22, 23] ), corn-soy blend ready-to-eat meal supplement (South Africa [32] ), fortified amylaseenriched maize product (South Africa [26] ), food supplementation or support (Malawi/Mozambique/ Guinea [10] , Ethiopia [8] , Cambodia [52] ), and multivitamins (Kenya [22] , South Africa [32] , Uganda [40] , Uganda/Zimbabwe [43] , and India [82] ). One (Kenya [22] ) study evaluated receipt and duration of nutritional supplementation in growth analyses, whereas a second study (Malawi [24] ) evaluated 6-month nutritional recovery in malnourished children initiating ART with ready-to-use therapeutic food. A third study (South Africa [32] ) evaluated dietary iron intake and changes in hemoglobin 18 months post-ART among children receiving iron-free multivitamins. Specific eligibility criteria for nutritional support were generally not defined. Two studies (United States [72] and Kenya [5] ) explicitly stated that children received no supplements. After adjusting for cohort age and setting, receipt of nutrition supplements was significantly associated with greater height gains at 12 and 24 months post-ART (0.38, 95% CI, 0.02, 0.74, P ¼ 0.04; and 0.60, 95% CI, 0.20, 1.01, P ¼ 0.007, respectively); this difference did not remain significant after adjusting for baseline cohort length (0.19, 95% CI À0.19 to 0.57, P ¼ 0.31; and 0.36, 95% CI À0.12 to 0.83, P ¼ 0.13, respectively). Similarly, there was better weight gain at 24 months in studies with supplements than without supplements (0.55, 95% CI 0.06-1.03, P ¼ 0.03); however, this relationship was not as strong after adjusting for baseline cohort weight (0.45, 95% CI À0.03 to 0.93, P ¼ 0.06).
ART regimen
Nine studies reported post-ART growth comparisons by regimen. Four of these (RLS ¼ 3 and developed settings ¼ 1) compared growth among children initiating protease inhibitor or nonnucleoside reverse-transcriptase inhibitor (NNRTI) based regimen. Two trials (Africa/ India [51] and Europe/Americas [83] ) reported significantly greater weight gains in nevirapine-naive children randomized to NNRTI vs. protease inhibitor-based regimens. Conversely, an observational study in Brazil [66] reported greater weight gains in children initiating protease inhibitor-based ART. After adjusting for cohort age and setting, rate of weight gain did not differ between studies reporting NNRTI vs. protease inhibitor-containing regimens (6 months: 0.13, 95% CI À0.48 to 0.73, P ¼ 0.67; 12 months: À0.31, 95% CI, À0.98 to 0.36, P ¼ 0.35); similar associations remained after adjusting for baseline cohort weight. Similarly, there was no difference in height velocity by regimen in adjusted analyses (6 months: 0.19, 95% CI À0.08 to 0.46, P ¼ 0.15; 12 months: 0.11, 95% CI À0.19 to 0.40, P ¼ 0.44). 
Discussion
In this systematic review and meta-analysis of 6, 12, and 24-month growth outcomes in HIV-infected children initiating ART, children in RLS had markedly lower weight and height at ART initiation compared with children in developed settings. Following ART, children in both settings experienced rapid improvements in weight and height. Whereas the greatest gains in weight were observed during the first 6 months of therapy, gains in height were more modest and occurred later. Children in RLS had significant improvements in WAZ and HAZ at 6 and 12 months post-ARTwith higher rates of weight gain at 12 and 24 months post-ART compared with children in developed settings. Despite substantial growth reconstitution following ART, children in RLS continued to be an average of 1 SD below that of children in developed settings at 12 months post-ART because of baseline differences that never recovered.
Younger age at ART initiation was associated with greater gains in growth in nine studies, irrespective of setting. The most marked improvements in weight and height velocity were observed in children initiating ART prior to 3 years of age [1, 22, 39, 42, 73] . In the two studies reporting no difference in growth based on age at ART, the first consisted of few children less than 2 years of age [57] , and the second reported high loss to follow-up rate and missing data [25] . Although older children do experience post-ART catch-up growth, they do not reconstitute as rapidly as younger children and they may never reach population age norms, particularly in height. These results emphasize the need for early identification and treatment of HIV in pediatric populations, as early ART initiation would be expected to avoid further growth compromise.
A few studies provided information on nutritional supplements, all from RLS [5, 8, 10, [22] [23] [24] [25] 32, 40, 44, 64, 72] . Although many ART programmes in RLS provide nutritional supplements during ART, most studies did not clearly specify eligibility criteria or duration of supplementation, and only two evaluated the impact of supplements on growth. A Kenyan study reported greater post-ART weight gain in children receiving food supplements, and greater gains in height with multivitamins [22] . In a South African study of dietary iron intake, post-ART height gains were associated with higher hemoglobin levels [32] . In other studies mentioning nutritional support [25, 44, 64] , the greatest gains in weight were among children with the lowest baseline WAZ at ART initiation. In the absence of HIV, catch-up growth to population norms following malnutrition depends on severity, duration, and age at onset [84] . International adoptees experience remarkable catch-up growth, with younger adoptees gaining as much as 2 SD in weight and height [85] . In Malawi, 80% of children recovered from moderate acute malnutrition after treatment with ready-to-use therapeutic supplementary food [86] . Although food supplements as an adjunct to ART may accelerate weight recovery, it is unclear whether ART alone would produce the same rebound in a slightly longer timeframe or if underlying poverty contributes to the persistence of undernutrition. Our pooled analysis suggests greater 12-month and 24month height and 24-month weight gains in cohorts using supplements; however, lack of direct comparison of growth outcomes by timing and supplement type makes it difficult to interpret these results. Further research is needed to determine effectiveness and optimal supplement regimens as adjuncts to ART.
Prior studies have yielded inconclusive data on the influence of ART regimen on growth reconstitution. The IMPAACT P1060 trial, undertaken in sub-Saharan Africa and India, reported better weight gains in the nevirapine (NVP) group compared with lopinavir/ ritonavir (LPV/r) group [51] . However, this difference did not remain after 1 year [87] . Conversely, the PENPACT trial in Europe and North and South America showed greater weight gain in the protease inhibitor group [88] . Similarly, a large observational study reported better weight and height growth among children initiating protease inhibitor-based vs. NNRTI-based regimens [89] . In practice, younger children are preferentially provided LPV/r-based regimens to reduce the likelihood of NVP resistance among those exposed to antiretrovirals for prevention of motherto-child transmission of HIV, which may confound ability to determine role of regimen in growth reconstitution. Despite concerns regarding poor palatability of LPV/r that could compromise adherence [26, 33] , a recent Cochrane review [90] concluded that LPV/r was a more efficacious first-line regimen than NVP among younger children. The relationship between post-ART growth gains and immune and viral response is not well understood. Post-ART gains in weight have been shown to correlate with improvements in CD4 þ and viral load [78, 79] ; conversely, other studies have shown no association between post-ART virologic response and growth recovery suggesting other factors are required to promote growth [19, 42, 77] . We found no difference in growth response between studies reporting protease inhibitor-based and NNRTI-based regimens, and many studies lacked statistical power to compare growth outcomes by regimen.
This study has limitations inherent to systematic reviews and meta-analyses. Retention varied across studies. Children no longer in care may have been more likely to have died or worse growth outcomes than those in care. This would lead to overestimating growth reconstitution following ART. The studies included older children (mean age 7 years) and could be affected by survivor bias. Studies of younger children may have greater post-ART growth recovery compared with older cohorts. However, there was no difference in mean age at baseline between RLS and developed settings. This analysis excluded some studies reporting growth in weight and length rather than z scores. However, most studies included z scores and we believe exclusion of studies without z scores does not introduce substantial bias into our estimates of pooled changes in growth.
Lastly, a few studies included children with prior mono/ dual therapy. Compared with treatment-naive children initiating ART, children with prior treatment may have a slower rate of post-ART growth. This is the first systematic review of post-ART growth outcomes in children in RLS and developed settings. Previous reviews of pediatric post-ART outcomes have included only baseline growth measures [14] or provided limited data on follow-up growth in sub-Saharan Africa or RLS [3, 12, 13] . We expanded upon this by systematically screening, evaluating, and selecting studies including post-ART growth outcomes irrespective of study setting. Meta-analysis techniques were then used to provide standardized summary statistics of change in growth at 6, 12, and 24 months post-ART; affording a unique opportunity to compare the rate of change in weight and height in children receiving ART across studies in RLS and developed settings.
Whereas post-ART rates of growth reconstitution in RLS and developed settings were comparable or higher in RLS, children in RLS had continued marked lower growth at 12 and 24 months post-ART. Projecting from 2-year growth reconstitution rates, if rates persisted at similar or lower reconstitution, it may take 4-5 years to reach population norms for WAZ, whereas HAZ is likely to never fully recover. Few studies reported data on nutritional supplementation, making it difficult to assess the potential benefits of supplementation. Current programmes often provide empiric nutritional supplementation to children starting ART, but it is not clear if this is beneficial because ART alone results in substantial growth reconstitution. Despite empiric nutritional supplementation in pediatric ART programmes evidence of the effectiveness of nutritional therapy on growth and morbidity in children on ART is lacking. Improvements in programmatic data regarding nutritional supplements can help inform policies to optimize nutritional therapy for growth reconstitution in children on ART. Our study demonstrates marked persistent growth compromise in ART-treated children. Earlier diagnosis and treatment of children and further data regarding the role of supplementation will be important to enhance growth in these children.
